COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn PVP-IPVP-I FLVFLV REGNR2 LY-CoVLY RemdesivirRMD
HCQ study #233 of 257
1/2 Late treatment study
Sarfaraz et al., medRxiv, doi:10.1101/2020.12.28.20248920 (Preprint)
Determinants of in-hospital mortality in COVID-19; a prospective cohort study from Pakistan
Source   PDF   Share   Tweet
Retrospective 186 hospitalized patients in Pakistan showing unadjusted HCQ mortality RR 1.45, p = 0.07. Confounding by indication is likely.

Sarfaraz et al., 1/2/2021, retrospective, Pakistan, South Asia, preprint, 7 authors.
risk of death, 45.0% higher, RR 1.45, p = 0.07, treatment 40 of 94 (42.6%), control 27 of 92 (29.3%).

Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.
Details of all 257 studies    Meta analysis
Please send us corrections, updates, or comments.